[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placenta-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placenta-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,71,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100592347","characterization-of-placental-diffusion-100592347",false,"NCT06992245","Characterization of Placental Diffusion","Characterization of Placental Diffusion in Women With Diabetes Using DW-MRI","Inclusion Criteria:\n\n* Women with PGAM (Pre-gestational diabetes) diagnosed before 20 weeks of pregnancy\n* Women with GDMA (Gestational diabetes) diagnosed by OGTT after 20 weeks of pregnancy\n\nExclusion Criteria:\n\n* pregnant women with placental hypoxia disease related in the past\n* pregnant women with placental hypoxia disease related in the present\n* non-singleton pregnancy\n* women in active labor or rupture of membrane\n* smoking women\n* suspicion of placenta accreta",true,"FEMALE","18 Years","50 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","DW-MRI Allows a quantitative comparison of diffusion as an expression of tissue hypoxia. The investigators aim is to compare changes in placental diffusion in pregnant women with uncontrolled diabetes compared to healthy pregnant women using DW-MRI.\n\nThe investigators hypothesize that placentas of diabetic mothers will show lower diffusion \u002F perfusion compared to placentas of healthy women.",[28,29],"Pregnancy in Diabetic","Placenta Diseases","RECRUITING","2025-12-18",{"date":33,"type":34},"2025-12-24","ACTUAL",{"date":36,"type":34},"2023-07-06",{"date":38,"type":22},"2027-12",{"name":40,"class":41},"Hillel Yaffe Medical Center","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100543215","effects-of-tuberculosis-infection-on-development-and-function-of-the-placenta-100543215","NCT06352970","Effects of Tuberculosis Infection on Development and Function of the Placenta","Effects of Tuberculosis Infection on Placental Development and Function","Inclusion Criteria:\n\n* Women admitted for delivery to study sites\n* Written informed consent\n* Age 18 years or greater\n\nExclusion Criteria:\n\n* Chronic comorbidities (other than TB, HIV or pregnancy-related disorder)\n* Twin pregnancy",{"count":51,"type":22},500,"OBSERVATIONAL","The goal of this observational study is to understand how tuberculosis (TB) infection impacts the function and development of the placenta, and whether TB infection can contribute to pregnancy-related disorders through effects on the placenta.\n\nThe main questions it aims to answer are:\n\n* Does TB infection affect the structure of the placenta?\n* Does TB infection affect the function of the placenta?\n\nPregnant women attending delivery clinics in Addis Abeba, Ethiopia, will be enrolled and classified for TB infection using a blood-based test. We will compare the following outcomes between women with TB infection and women without TB infection:\n\n* Pathological lesions of the placenta\n* Gene and protein expression patterns linked to pregnancy-related disorders\n* Infant outcome at birth and at 6 weeks after birth",[55,56,29],"Pregnancy Related","Tuberculosis Infection",[58,59,60],"placenta","tuberculosis","pregnancy complication","2025-03-14",{"date":63,"type":34},"2025-03-17",{"date":65,"type":34},"2024-10-01",{"date":67,"type":22},"2027-12-31",{"name":69,"class":70},"Lund University","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100461118","management-of-early-onset-fetal-growth-restriction-angiogenic-factors-versus-feto-placental-doppler-100461118","NCT05284474","Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler","Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler (Early GRAFD)","earlyGRAFD","Inclusion Criteria:\n\n* Pregnant women of at least 18 years old\n* Singleton pregnancy\n* Ultrasonographic EFW ≤10th percentile between 26+0 and 31+6 weeks of gestation\n* Gestational age confirmed by fetal crown-rump length measurement during the first trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates.\n\nExclusion Criteria:\n\n* Major fetal malformations or genetic disorders\n* Fetal death\n* Refusal to give informed consent\n* Stage IV FGR",{"count":80,"type":22},340,[25],"This is a multicentre, open-label, randomized controlled trial. A total of 340 singleton pregnancies with an EFW ≤10th percentile between 26+0 and 31+6 weeks will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, different soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1\u002FPlGF) cutoffs will be incorporated to the current protocol to adjust the frequency of ultrasounds and to plan elective delivery.",[84,85,29],"Fetal Growth Retardation","Preeclampsia",[87,88,89,90,91],"fetal growth restriction","small for gestational age","PlGF","sFlt-1","Doppler","NOT_YET_RECRUITING","2024-06-03",{"date":95,"type":34},"2024-06-04",{"date":93,"type":22},{"date":98,"type":22},"2026-12-30",{"name":100,"class":70},"Hospital Universitari Vall d'Hebron Research Institute",27,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100506255","gestational-diabetes-mellitus-placental-maternal-crosstalk-and-future-health-100506255","NCT05872009","Gestational Diabetes Mellitus: \"Placental-maternal Crosstalk and Future Health\"","The GaP Study: Gestational Diabetes Mellitus: \"Placental-maternal Crosstalk and Future Health","GaP","Inclusion Criteria:\n\n* Pregnant women \\>18 years with GDM giving birth at Oslo University hospital Ullevål.\n* Control group of gestational age matched euglycemic, normotensive pregnancies\n\nExclusion Criteria:\n\n* reduced fetal movements,\n* epilepsy\n* thyroidea dysfunction\n* hypertensive disorder of pregnancy\n* non-communicable disease\n* Communicable disease (such as HIV)\n* type 1 or type 2 diabetes.\n* not able to understand Norwegian or English.\n* under legal guardianship.",{"count":111,"type":22},350,"The GaP study is designed to close important knowledge gaps by:\n\n1. exploring placental health and cellular ageing in GDM and the association with neonatal outcome\n2. evaluating the effectiveness of current and novel maternal health follow-up strategies after GDM",[114,115,29],"Gestational Diabetes","Cardiovascular Diseases","2023-05-22",{"date":118,"type":34},"2023-05-23",{"date":120,"type":22},"2023-06-01",{"date":122,"type":22},"2026-06",{"name":124,"class":70},"Oslo University Hospital"]